11.20.2023
Improve Outcomes
$1,217,662.00
18 months
Leveraging new ultra-rapid insulins with AID for exercise management with T1D
Evaluate the safety and efficacy of two new ultra-rapid insulins, Lyumjev and Afrezza, for better management of exercise-related hypoglycemia and hyperglycemia in adults living with T1D using Automated Insulin Delivery (AID) systems.